JAC Advance Access originally published online on November 25, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 65-73
© 2004 The British Society for Antimicrobial Chemotherapy
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method
1 Unidad de Investigación de Diseño de Fármacos y Conectividad Molecular, Departamento de Química Física, Facultad de Farmacia, Universitat de València, 46100 Burjassot, Valencia; 2 Institut de Química Computacional, Universitat de Girona, 17071 Girona; 3 Departamento de Microbiología, Facultad de Medicina y Odontología, Universitat de València, Av. Blasco Ibáñez 15, 46010 Valencia, Spain
Received 27 March 2003; returned 18 July 2003; revised 25 September 2003; accepted 3 October 2003
Objectives: In order to select new drugs and to predict their in vitro activity against Mycobacterium avium complex (MAC), new quantitative structureactivity relationship (QSAR) models were developed.
Methods: The activities against MAC of 29 structurally heterogeneous drugs were examined by means of linear discriminant analysis (LDA) and multilinear regression analysis (MLRA) by using topological indices (TI) as structural descriptors. In vitro antimycobacterial activities were determined by a broth microdilution method with 7H9 medium.
Results: The topological model obtained successfully classifies over 80% of compounds as active or inactive; consequently, it was applied in the search for new molecules active against MAC. From among the selected candidates demonstrating in vitro activity, aflatoxin B1, benzalkonium chloride and pentamidine stand out, with MIC50s between 4 and 32 mg/L.
Conclusion: The method described in this work is able to select molecules active against MAC.
Keywords: MAC, QSAR studies, topological indices
* Corresponding author. Tel: +34-963-544-891; Fax: +34-963-544-892; E-mail: jorge.galvez{at}uv.es
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Mahmoudi, R. Garcia-Domenech, J. Galvez, K. Farhati, J.-F. Franetich, R. Sauerwein, L. Hannoun, F. Derouin, M. Danis, and D. Mazier New Active Drugs against Liver Stages of Plasmodium Predicted by Molecular Topology Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1215 - 1220. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mahmoudi, J.-V. de Julian-Ortiz, L. Ciceron, J. Galvez, D. Mazier, M. Danis, F. Derouin, and R. Garcia-Domenech Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening J. Antimicrob. Chemother., March 1, 2006; 57(3): 489 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Guna, C. Munoz, V. Dominguez, A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, and R. Borras In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii J. Antimicrob. Chemother., June 1, 2005; 55(6): 950 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Garcia-Garcia, J. Galvez, J. V. de Julian-Ortiz, R. Garcia-Domenech, C. Munoz, R. Guna, and R. Borras Search of Chemical Scaffolds for Novel Antituberculosis Agents J Biomol Screen, April 1, 2005; 10(3): 206 - 214. [Abstract] [PDF] |
||||


